Compare COUR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | GHRS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 947.2M |
| IPO Year | 2021 | 2021 |
| Metric | COUR | GHRS |
|---|---|---|
| Price | $5.08 | $22.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | $10.53 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 5.9M | 251.0K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $757,500,000.00 | N/A |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.04 | N/A |
| 52 Week Low | $5.00 | $10.67 |
| 52 Week High | $13.56 | $24.66 |
| Indicator | COUR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 64.04 |
| Support Level | N/A | $12.41 |
| Resistance Level | $6.41 | $22.88 |
| Average True Range (ATR) | 0.35 | 1.32 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 2.45 | 76.22 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.